المؤلفون: van der Wall, Sake J., van Rein, Nienke, van den Bemt, Bart, Kruip, Marieke J. H. A., Meijer, Karina, te Boome, Liane C. J., Simmers, Tim A., Alings, A. MarcoW., Tieleman, Robert, Westerweel, Peter E., Klok, FrederikusA., Huisman, MennoV.

المصدر: van der Wall , S J , van Rein , N , van den Bemt , B , Kruip , M J H A , Meijer , K , te Boome , L C J , Simmers , T A , Alings , A M , Tieleman , R , Westerweel , P E , Klok , F & Huisman , M 2019 , ' Performance of idarucizumab as antidote of dabigatran in daily clinical practice ' , Europace , vol. 21 , no. 3 , pp. 414-420 . https://doi.org/10.1093/europace/euy220

مصطلحات موضوعية: Idarucizumab, Dabigatran, Bleeding, Reversal, PROTHROMBIN COMPLEX CONCENTRATE, VITAMIN-K ANTAGONISTS, ORAL ANTICOAGULANTS, MANAGEMENT, HEMORRHAGE, SAFETY, STROKE, CARE, SSC

وصف الملف: application/pdf

Relation: https://research.rug.nl/en/publications/041f9e2a-c7e1-4eb6-a6c0-9b1692fcb54d

الاتاحة: https://hdl.handle.net/11370/041f9e2a-c7e1-4eb6-a6c0-9b1692fcb54d
https://research.rug.nl/en/publications/041f9e2a-c7e1-4eb6-a6c0-9b1692fcb54d
https://doi.org/10.1093/europace/euy220
https://pure.rug.nl/ws/files/92375202/euy220.pdf